

Financial news for JAZZ dated on 2020-06-01: 10 Biggest Price Target Changes For Monday

Financial news for JAZZ dated on 2020-06-01: SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to \$169

Financial news for JAZZ dated on 2020-05-30: Notable Insider Buys: Avis, Dynavax And Formula One

Financial news for JAZZ dated on 2020-05-14: Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings

Financial news for JAZZ dated on 2020-05-11: Bionical Emas And Jazz Pharmaceuticals Enter Into An Agreement For Expanded Access To Lurbinectedin In Relapsed Small Cell Lung Cancer In The United States

Financial news for JAZZ dated on 2020-05-06: SunTrust Robinson Humphrey Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target of \$153

Financial news for JAZZ dated on 2020-05-06: BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to \$193

Financial news for JAZZ dated on 2020-05-06: SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to \$160

Financial news for JAZZ dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for JAZZ dated on 2020-05-05: Jazz Pharmaceuticals shares are trading lower after the company reported Q1 EPS is down year over year and worse-than-expected Q1 sales results. The company also cut FY20 sales guidance.

Financial news for JAZZ dated on 2020-05-05: Jazz Pharmaceuticals Cuts FY20 Sales Guidance From \$2.32B-\$2.4B To \$2.12B-\$2.26B Vs. \$2.48B Est.

Financial news for JAZZ dated on 2020-05-05: Jazz Pharmaceuticals Q1 EPS \$(2.820) Down From \$1.470 YoY, Sales \$535.000M Miss \$543.590M Estimate

Financial news for JAZZ dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for JAZZ dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for JAZZ dated on 2020-04-30: Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to \$162

Financial news for JAZZ dated on 2020-04-30: Oppenheimer Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to \$141

Financial news for JAZZ dated on 2020-04-29: Jazz Pharmaceuticals Stops Enrollment For Its Phase 3 Study Evaluating Defibrotide For The Prevention Of Veno-Occlusive Disease

Financial news for JAZZ dated on 2020-04-16: Jazz Pharmaceuticals Says Porton Biopharma Limited Entered Into New Agreement With New Partner to Commercialize & Distribute Erwinaze

Financial news for JAZZ dated on 2020-04-06: Jefferies Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target to \$149

Financial news for JAZZ dated on 2020-04-02: Morgan Stanley Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to \$109

Financial news for JAZZ dated on 2020-03-31: Jazz Pharmaceuticals Says It Has Over \$1 Billion In Cash and In Investments, The Company Sees A Limited Financial Impact Due To Coronavirus

Financial news for JAZZ dated on 2020-03-26: 7 Stocks To Watch For March 26, 2020

Financial news for JAZZ dated on 2020-03-25: 6 Stocks Moving In Wednesday's After-Hours Session

Financial news for JAZZ dated on 2020-03-25: Jazz Pharmaceuticals shares are trading higher after the company announced FDA acceptance of its New Drug Application for JZP-258.

Financial news for JAZZ dated on 2020-03-25: Jazz Pharmaceuticals Announces FDA

Acceptance Of New Drug Application For JZP-258 For Cataplexy And Excessive Daytime Sleepiness Associated With Narcolepsy

Financial news for JAZZ dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for JAZZ dated on 2020-03-23: B of A Securities Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to \$163

Financial news for JAZZ dated on 2020-03-18: Zoetis Shares Up 5% After Hours; SunTrust Earlier Discussed Expectations Drugmakers Won't See Near-Term Debt Crisis, Sees Co., Jazz Pharma As Strongest Positioned In Terms Of Debt, Leverage

Financial news for JAZZ dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for JAZZ dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for JAZZ dated on 2020-03-12: Benzinga's Top Upgrades, Downgrades For March 12, 2020

Financial news for JAZZ dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for JAZZ dated on 2020-03-12: Bernstein Upgrades Jazz Pharmaceuticals to Outperform, Lowers Price Target to \$166

Financial news for JAZZ dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for JAZZ dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for JAZZ dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for JAZZ dated on 2020-02-27: SunTrust Robinson Humphrey Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to \$166

Financial news for JAZZ dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for JAZZ dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for JAZZ dated on 2020-02-26: BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to \$205

Financial news for JAZZ dated on 2020-02-26: JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to \$183

Financial news for JAZZ dated on 2020-02-25: Jazz Pharmaceuticals Sees FY20 Sales \$2.320B-\$2.4B Vs \$2.36B Estimates

Financial news for JAZZ dated on 2020-02-25: Jazz Pharmaceuticals Q4 EPS \$4.42 Beats \$4.12 Estimate, Sales \$581.74M Beat \$561.69M Estimate

Financial news for JAZZ dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for JAZZ dated on 2020-02-25: Earnings Scheduled For February 25, 2020

Financial news for JAZZ dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for JAZZ dated on 2020-02-18: PharmaMar And Jazz Pharmaceuticals On Monday Announced FDA Acceptance And Priority Review Of New Drug Application For Lurbinectedin In Relapsed Small Cell Lung Cancer

Financial news for JAZZ dated on 2020-02-05: Jazz Pharma Shares Volatile As Hearing FDA Says Reports Of Serious Risk Of Suicidal Behavior In Patients Taking Co.'s Sunosi

Financial news for JAZZ dated on 2020-01-22: Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to \$189

Financial news for JAZZ dated on 2020-01-22: Jazz Pharmaceuticals Submits New Drug

Application For JZP-258 For Cataplexy And Excessive Daytime Sleepiness Associated With Narcolepsy

Financial news for JAZZ dated on 2020-01-22: PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

Financial news for JAZZ dated on 2020-01-20: Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Financial news for JAZZ dated on 2019-12-30: Jazz Pharmaceuticals Announces First Patient Enrolled In Pivotal Phase 2/3 Study Evaluating JZP-458 For Treatment Of Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma

Financial news for JAZZ dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for JAZZ dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for JAZZ dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for JAZZ dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for JAZZ dated on 2019-12-19: PharmaMar, Jazz Pharma Report Exclusive License Deal for Lurbinectedin In US

Financial news for JAZZ dated on 2019-12-18: Pfenex Earns \$15M Development Milestone Under Its Development And License Agreement With Jazz Pharmaceuticals

Financial news for JAZZ dated on 2019-12-03: Wells Fargo Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to \$186

Financial news for JAZZ dated on 2019-12-02: 10 Biggest Price Target Changes For Monday

Financial news for JAZZ dated on 2019-12-02: Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to \$200

Financial news for JAZZ dated on 2019-11-15: EU's CHMP Gives Positive Opinion For Jazz Pharma's Sunosi For Treatment Of Excessive Daytime Sleepiness

Financial news for JAZZ dated on 2019-11-05: Jazz Pharmaceuticals Q3 Adj. EPS \$4.1 Beats \$3.59 Estimate, Sales \$537.702M Beat \$525.16M Estimate

Financial news for JAZZ dated on 2019-11-05: Earnings Scheduled For November 5, 2019

Financial news for JAZZ dated on 2019-10-14: Bernstein Earlier Reinstated Market Perform on Jazz Pharmaceuticals, Announced \$150 Price Target

Financial news for JAZZ dated on 2019-10-10: Jazz Pharmaceuticals Announces First Patient Enrolled In Phase 2 Clinical Trial Evaluating Defibrotide For The Prevention Of CAR-T Associated Neurotoxicity

Financial news for JAZZ dated on 2019-10-08: 5 Stocks To Watch For October 8, 2019

Financial news for JAZZ dated on 2019-10-07: Jazz Pharmaceuticals CFO Matthew Young To Resign

Financial news for JAZZ dated on 2019-10-03: Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

Financial news for JAZZ dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for JAZZ dated on 2019-09-06: The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication

Financial news for JAZZ dated on 2019-08-21: Benzinga's Top Upgrades, Downgrades For August 21, 2019

Financial news for JAZZ dated on 2019-08-21: 10 Biggest Price Target Changes For Wednesday

Financial news for JAZZ dated on 2019-08-21: Piper Jaffray Downgrades Jazz Pharmaceuticals to Neutral, Lowers Price Target to \$142

Financial news for JAZZ dated on 2019-08-13: The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelson Delays Quarterly Results

Financial news for JAZZ dated on 2019-08-12: Jazz Pharmaceuticals Acquires Cavion; Cavion Shareholders To Receive Upfront Payment Of \$52.5M And Up To \$260M In Milestone Payments

Financial news for JAZZ dated on 2019-08-06: Jazz Pharma Raises FY19 Sales Guidance From \$2.05B-\$2.13B To \$2.07B-\$2.15B vs \$2.09B Estimate, Reaffirms Adj. EPS Guidance \$14.30-\$15 vs \$14.81 Est.

Financial news for JAZZ dated on 2019-08-06: Jazz Pharmaceuticals Q2 EPS \$4.05 Beats \$3.58 Estimate, Sales \$534.133M Beat \$508.83M Estimate

Financial news for JAZZ dated on 2019-08-06: Jazz Pharma Reports Advancement Of Recombinant Crisantaspase Development Program; Phase 1 Study Complete, Phase 2/3 Study Expected To Begin Later In 2019

Financial news for JAZZ dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for JAZZ dated on 2019-08-06: Earnings Scheduled For August 6, 2019

Financial news for JAZZ dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for JAZZ dated on 2019-07-15: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for JAZZ dated on 2019-07-10: The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV

Financial news for JAZZ dated on 2019-07-10: Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma for \$3.5M Upfront, Up to \$203M in Milestones

Financial news for JAZZ dated on 2019-07-03: 8 Biggest Price Target Changes For Wednesday

Financial news for JAZZ dated on 2019-06-17: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for JAZZ dated on 2019-06-17: Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi

Financial news for JAZZ dated on 2019-06-11: Barclays Initiates Coverage On Jazz Pharmaceuticals with Overweight Rating, Announces \$164 Price Target

Financial news for JAZZ dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for JAZZ dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for JAZZ dated on 2019-05-09: Jazz Pharmaceuticals Announces That 14 Abstracts Sponsored By Co. And One Abstract From An Investigator-Sponsored Trial Will Be Presented At The 33rd Annual Meeting Of The Associated Professional Sleep Societies June 8-12

Financial news for JAZZ dated on 2019-05-08: Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results and reaffirmed FY19 guidance. BMO Capital maintained an Outperform rating on the stock.

Financial news for JAZZ dated on 2019-05-08: Mizuho Maintains Neutral on Jazz Pharmaceuticals plc - Ordinary Shares, Raises Price Target to \$148

Financial news for JAZZ dated on 2019-05-08: BMO Capital Maintains Outperform on Jazz Pharmaceuticals plc - Ordinary Shares, Raises Price Target to \$208

Financial news for JAZZ dated on 2019-05-07: Jazz Pharma Reaffirms FY19 Guidance: Adj. EPS \$14.30-\$15 vs \$14.60 Estimate, Sales \$2.05B-\$2.13B vs \$2.07B Est.

Financial news for JAZZ dated on 2019-05-07: Jazz Pharmaceuticals Q1 Adj. EPS \$3.67 Beats \$3.16 Estimate, Sales \$508.186M Beat \$465.95M Estimate

Financial news for JAZZ dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies,

Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for JAZZ dated on 2019-05-07: Earnings Scheduled For May 7, 2019

Financial news for JAZZ dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for JAZZ dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for JAZZ dated on 2019-04-17: Betaville Article Discusses Trader Speculation Of Jazz Pharmaceuticals Interest In Acquiring TG Therapeutics

Financial news for JAZZ dated on 2019-04-04: 'Three drug makers settle allegations of using charities to pay kickbacks to Medicare patients' -Stat News

Financial news for JAZZ dated on 2019-04-04: UPDATE: Jazz Pharma To Pay \$57M Plus Interest At 2.75%

Financial news for JAZZ dated on 2019-04-04: Jazz Pharma 8-K Shows Entered Civil Settlement Deal With US Dept. Of Justice, Office Of Inspector General Of Dept. Of Health And Human Services

Financial news for JAZZ dated on 2019-03-27: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

Financial news for JAZZ dated on 2019-03-26: UPDATE: Jazz Says 'Two patients experienced serious adverse events (SAEs) that were considered by the investigator to be treatment related.'

Financial news for JAZZ dated on 2019-03-26: UPDATE: Jazz Pharma Says 'treatment-emergent adverse events that occurred in $\geq 5\%$ of patients who received JZP-258 were headache, nausea, dizziness, cataplexy, nasopharyngitis, decreased appetite, influenza, diarrhea and vomiting'

Financial news for JAZZ dated on 2019-03-26: Jazz Pharma Reports Top-Line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness: Achieved Primary, Key Secondary Endpoints

Financial news for JAZZ dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for JAZZ dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for JAZZ dated on 2019-03-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for JAZZ dated on 2019-03-20: The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

Financial news for JAZZ dated on 2019-03-20: SunTrust Robinson Humphrey Initiates Coverage On Jazz Pharmaceuticals with Buy Rating

Financial news for JAZZ dated on 2019-03-16: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for JAZZ dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for JAZZ dated on 2019-03-08: Morgan Stanley Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to \$135

Financial news for JAZZ dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for JAZZ dated on 2019-02-28: 84 Biggest Movers From Yesterday

Financial news for JAZZ dated on 2019-02-27: 72 Stocks Moving In Wednesday's Mid-Day Session

Financial news for JAZZ dated on 2019-02-27: Jazz Pharmaceuticals shares are trading higher after the company beat Q4 sales and EPS estimates; the company also provided FY19 sales guidance above analyst estimates.

Financial news for JAZZ dated on 2019-02-27: BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to \$206

Financial news for JAZZ dated on 2019-02-27: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JAZZ dated on 2019-02-27: The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

Financial news for JAZZ dated on 2019-02-26: 6 Stocks Moving In Tuesday's After-Hours Session

Financial news for JAZZ dated on 2019-02-26: Jazz Pharma Sees FY19 Sales \$2.05B-\$2.13B vs \$2.03B Estimate

Financial news for JAZZ dated on 2019-02-26: Jazz Pharmaceuticals Q4 Adj. EPS \$3.64 Beats \$3.02 Estimate, Sales \$476.457M Beat \$459.72M Estimate

Financial news for JAZZ dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for JAZZ dated on 2019-02-26: Earnings Scheduled For February 26, 2019

Financial news for JAZZ dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for JAZZ dated on 2019-01-03: Jazz Pharmaceuticals Announces Cancer Treatment Collaboration Collaboration With Codiak BioSciences; Co. Will Pay Codiak \$56M Upfront And Up To \$200M In Milestones Per Target

Financial news for JAZZ dated on 2018-12-21: Jazz Pharmaceuticals Receives New PDUFA Goal Date Of March 20 For Solriamfetol In Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

Financial news for JAZZ dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for JAZZ dated on 2018-12-16: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for JAZZ dated on 2018-12-12: Benzinga's Top Upgrades, Downgrades For December 12, 2018

Financial news for JAZZ dated on 2018-12-12: Oppenheimer Initiates Coverage On Jazz Pharmaceuticals with Outperform Rating, Announces \$180 Price Target

Financial news for JAZZ dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for JAZZ dated on 2018-12-10: Jazz Pharma Adds \$400M To Buyback

Financial news for JAZZ dated on 2018-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for JAZZ dated on 2018-11-29: Jazz Pharmaceuticals Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating JZP-258 For The Treatment Of Idiopathic Hypersomnia

Financial news for JAZZ dated on 2018-11-08: B. Riley FBR Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to \$190

Financial news for JAZZ dated on 2018-11-08: 88 Biggest Movers From Yesterday

Financial news for JAZZ dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for JAZZ dated on 2018-11-06: Jazz Pharmaceuticals plc Q3 EPS \$3.58 Beats \$3.32 Estimate, Sales \$469.373M Miss \$482.21M Estimate

Financial news for JAZZ dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for JAZZ dated on 2018-11-06: Earnings Scheduled For November 6, 2018

Financial news for JAZZ dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for JAZZ dated on 2018-10-29: Jazz Pharmaceuticals Announces FDA Approval of Xyrem for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Financial news for JAZZ dated on 2018-10-22: Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report

Financial news for JAZZ dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for JAZZ dated on 2018-10-11: UPDATE: Jazz Is Entitled To Receive A Meaningful Royalty On Net Sales Of Amneal Product 'as well as payment for the supply of the Amneal AG Product and reimbursement for a portion of the services costs associated with distribution...'

Financial news for JAZZ dated on 2018-10-11: UPDATE: Jazz Pharma Settlement Dictates Amneal Will Have Non-Exclusive Rights To Sell Limited Volume Of An Authorized Generic Version Of Xyrem From Jul. 1, 2023 To Dec. 31, 2025 Or Earlier Under Certain Circumstances

Financial news for JAZZ dated on 2018-10-11: Jazz Pharma 8-K Shows Co. Settled Ongoing Patent Litigation Against Amneal Pharma Related To Amneal's ANDA Seeking To Market Generic Xyrem

Financial news for JAZZ dated on 2018-09-26: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for JAZZ dated on 2018-09-18: REMINDER: Jazz Pharma Holding Webcast Today To Discuss Vyxeos Launch

Financial news for JAZZ dated on 2018-09-17: The Week Ahead: Alibaba Investor Day, FedEx Earnings, Eventbrite IPO

Financial news for JAZZ dated on 2018-08-27: Jazz Pharmaceuticals Earlier Announced That The European Commission Has Approved Vyxeos For Myeloid Leukaemia

Financial news for JAZZ dated on 2018-08-08: 10 Biggest Price Target Changes For Wednesday

Financial news for JAZZ dated on 2018-08-08: BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to \$206

Financial news for JAZZ dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for JAZZ dated on 2018-08-08: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JAZZ dated on 2018-08-08: Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to \$205

Financial news for JAZZ dated on 2018-08-07: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for JAZZ dated on 2018-08-07: Jazz Reaffirms FY18 Guidance: Adj. EPS \$12.75-\$13.25 vs \$13.09 Estimate, Sales \$1.88B-\$1.93B vs \$1.9B Est.

Financial news for JAZZ dated on 2018-08-07: Jazz Raises FY18 Xyrem Sales Guidance To \$1.35B-\$1.38B

Financial news for JAZZ dated on 2018-08-07: Jazz Pharmaceuticals Q2 EPS \$3.49 Beats \$3.23 Estimate, Sales \$500.479M Beat \$469.62M Estimate

Financial news for JAZZ dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for JAZZ dated on 2018-08-07: Earnings Scheduled For August 7, 2018

Financial news for JAZZ dated on 2018-08-06: Jazz Pharma Reports Collaboration With MD Anderson Cancer Center For Evaluation Of Potential Treatment Options For Hematologic Malignancies

Financial news for JAZZ dated on 2018-08-03: Jazz Pharma Reports Centers for Medicare and Medicaid Services Has Granted New Technology Add-On Payment To Vyxeos Liposome For Injection

Financial news for JAZZ dated on 2018-07-19: Journal Of Clinical Oncology publishes PivotalPhase 3 Data For Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome For Injection

Financial news for JAZZ dated on 2018-07-13: Evercore's Umer Raffat Says Today's Patent Ruling On Jazz Pharmaceuticals Is A Non-Issue And 'Not Particularly Relevant For Xyrem's Patent Estate'

Financial news for JAZZ dated on 2018-07-13: Appeals Court Rejects Jazz Pharmaceutical's Bid To Revive Patents On Xyrem, Ruling Clears Way For Amneal Pharmaceutical's Luanch Of A Generic Version Of Xyrem

Financial news for JAZZ dated on 2018-07-11: Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target

Financial news for JAZZ dated on 2018-07-11: Benzinga's Top Upgrades, Downgrades For July 11, 2018

Financial news for JAZZ dated on 2018-07-11: The Market In 5 Minutes: More Tariffs, App Store's Birthday, PPI Data And More

Financial news for JAZZ dated on 2018-07-11: Morgan Stanley Downgrades Jazz Pharmaceuticals to Equal-Weight

Financial news for JAZZ dated on 2018-07-10: Citigroup Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to \$205

Financial news for JAZZ dated on 2018-06-29: Jazz Pharma Enters Agreement With TerSera Therapetucis To Sell Its Rights To Prialt For \$80M

Financial news for JAZZ dated on 2018-06-29: Jazz Pharma Reports Vyxeos Received Positive CHMP Opinion For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukemia

Financial news for JAZZ dated on 2018-06-27: Jazz Pharma Announces FDA Acceptance of SNDA For Xyrem

Financial news for JAZZ dated on 2018-06-26: B. Riley FBR Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to \$219

Financial news for JAZZ dated on 2018-06-21: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

Financial news for JAZZ dated on 2018-06-20: Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

Financial news for JAZZ dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for JAZZ dated on 2018-06-03: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Financial news for JAZZ dated on 2018-06-03: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem in Pediatric Patients with Narcolepsy with Cataplexy

Financial news for JAZZ dated on 2018-06-01: Bernstein Strategic Decisions 2018 Conference Concludes Today, Presenters Include: Colgate-Palmolive, KKR, JP MORGAN, Sabre, Alnylam, Jazz Pharmaceuticals, Valvoline, Lam Research, and Ally Financial

Financial news for JAZZ dated on 2018-05-10: B. Riley FBR Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to \$211

Financial news for JAZZ dated on 2018-05-09: BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to \$201

Financial news for JAZZ dated on 2018-05-09: Jazz Pharmaceuticals Agreed to Pay \$57M to Resolve U.S. Investigation of Financial Support of Charities that offer Assistance to Medicare Patients

Financial news for JAZZ dated on 2018-05-08: Jazz Pharma Sees FY18 Adj. EPS \$12.75-\$13.25 vs \$13 Est., Sales \$1.88B-\$1.93B vs \$1.89B Est.

Financial news for JAZZ dated on 2018-05-08: Jazz Pharmaceuticals Q1 Adj. EPS \$2.98 Beats \$2.77 Estimate, Sales \$444.613M Beat \$434.87M Estimate

Financial news for JAZZ dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for JAZZ dated on 2018-05-08: Earnings Scheduled For May 8, 2018

Financial news for JAZZ dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for JAZZ dated on 2018-05-01: Jazz Pharma Reports Submission Of sNDA For Xyrem To Treat Cataplexy, Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

Financial news for JAZZ dated on 2018-04-30: Merger Monday Makes A Return

Financial news for JAZZ dated on 2018-04-30: Spark Therapeutics Sells Priority Review Voucher for \$110M To Jazz Pharmaceuticals

Financial news for JAZZ dated on 2018-03-19: Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential

Financial news for JAZZ dated on 2018-03-19: Benzinga's Top Upgrades, Downgrades For March 19, 2018

Financial news for JAZZ dated on 2018-03-19: Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight

Financial news for JAZZ dated on 2018-03-02: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Financial news for JAZZ dated on 2018-03-01: Exclusive: Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable'

Financial news for JAZZ dated on 2018-02-28: BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to \$199.00

Financial news for JAZZ dated on 2018-02-27: Jazz Pharma Sees 2018 Adj. EPS \$12.65-\$13.25 vs. \$13.07 Est., Sales \$1.86B-\$1.93B vs. \$1.85B Est.

Financial news for JAZZ dated on 2018-02-27: Jazz Pharma Reports Q4 Adj. EPS \$2.95 vs. \$3.01 Est., Sales \$436.4M vs. \$441.3M Est.

Financial news for JAZZ dated on 2018-02-27: Jazz Pharmaceuticals Q4 Earnings Outlook

Financial news for JAZZ dated on 2018-02-27: Earnings Scheduled For February 27, 2018

Financial news for JAZZ dated on 2018-02-25: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for JAZZ dated on 2018-02-23: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Financial news for JAZZ dated on 2018-02-08: National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos Liposome for Injection to Clinical Practice Guidelines in Oncology

Financial news for JAZZ dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for JAZZ dated on 2018-01-02: Leerink Initiates Coverage On Jazz Pharmaceuticals with Outperform Rating, Announces \$180.00 Price Target

Financial news for JAZZ dated on 2017-12-21: Cowen Out Positive On Jazz Pharmaceuticals, Says Accelerating Growth Is Ahead, Would Add Into This Soon To An 'Undervalued' Growth Story

Financial news for JAZZ dated on 2017-12-21: Cantor Out Positive On Jazz Pharmaceutical, Says Next Leg Of Sleep Franchise Growth Is Established With NDA Filing of JZP-110; Firm Believes pitolisant Is Unlikely To Mount A Credible Competition To Xyrem or JZP-110

Financial news for JAZZ dated on 2017-12-21: Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol

Financial news for JAZZ dated on 2017-12-04: Jazz Pharmaceuticals Names Daniel Swisher COO

Financial news for JAZZ dated on 2017-11-10: Benzinga's Top Upgrades, Downgrades For November 10, 2017

Financial news for JAZZ dated on 2017-11-10: H.C. Wainwright Assumes Jazz Pharmaceuticals PLC at Neutral, Announces price target \$150.00

Financial news for JAZZ dated on 2017-11-07: 13 Stocks Moving In Tuesday's After-

Hours Session

Financial news for JAZZ dated on 2017-11-07: Jazz Pharma Sees FY17 Adj. EPS \$10.70-\$11.20 vs \$10.89 Est., Sales \$1.6B-\$1.65B vs \$1.64B Est.

Financial news for JAZZ dated on 2017-11-07: Jazz Pharma Reports Q3 Adj. EPS \$3.22 vs \$2.89 Est., Sales \$411.855M vs \$421M Est.

Financial news for JAZZ dated on 2017-11-07: Earnings Scheduled For November 7, 2017

Financial news for JAZZ dated on 2017-11-03: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency

Financial news for JAZZ dated on 2017-10-19: Benzinga's Top Upgrades, Downgrades For October 19, 2017

Financial news for JAZZ dated on 2017-10-19: FBR Capital Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Buy Rating, Announces \$206.00 Price Target

Financial news for JAZZ dated on 2017-09-28: Goldman Sachs Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Neutral Rating, Announces \$165.00 Price Target

Financial news for JAZZ dated on 2017-08-29: ImmunoGen Higher After Announcing Strategic Collaboration With Jazz Pharma

Financial news for JAZZ dated on 2017-08-29: Jazz Pharma and ImmunoGen Announces Agreement Granting Jazz Worldwide Rights to Opt into Development and Commercialization of 2 Early Stage Drugs, Jazz to Pay \$75M Upfront

Financial news for JAZZ dated on 2017-08-28: Benzinga's Top Upgrades, Downgrades For August 28, 2017

Financial news for JAZZ dated on 2017-08-25: Benzinga's Top Upgrades, Downgrades For August 25, 2017

Financial news for JAZZ dated on 2017-08-25: H.C. Wainwright Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Neutral Rating, Announces \$144.00 Price Target

Financial news for JAZZ dated on 2017-08-08: Jazz Pharmaceuticals Reports Q2 Adj. EPS \$2.56 vs \$2.75 Est., Sales \$394.386M vs \$410.82M Est.

Financial news for JAZZ dated on 2017-08-08: Earnings Scheduled For August 8, 2017

Financial news for JAZZ dated on 2017-08-03: Janney Out Positive On Jazz, Says Not Only Did They Get FDA Approval Of Vyxeos, But It Came With Broadest Possible Label; Raises Price Target From \$180 to \$192 And Reiterates Buy Rating

Financial news for JAZZ dated on 2017-08-03: FDA Approves Jazz Pharma's Vyxeos

Financial news for JAZZ dated on 2017-08-03: Companies Holding Shareholder Meetings Today Include Apollo Investment, Booz Allen Hamilton, CorVel, Eagle Materials, Electronic Arts, Gladstone Investment, Jazz Pharmaceuticals, Michael Kors, Progressive, and Sprint

Financial news for JAZZ dated on 2017-07-26: Jazz Pharma Enters License Agreement With XL-protein GmbH For Commercial Rights To PASylation Technology; Jazz Made \$2M Upfront Payment

Financial news for JAZZ dated on 2017-06-20: Jazz Pharma Downgraded By Vetr

Financial news for JAZZ dated on 2017-06-13: Goldman Sachs Global Healthcare Conference Begins Today, Presenters Include Mallinckrodt, Jazz Pharma, Community Health, and Juno Therapeutics

Financial news for JAZZ dated on 2017-06-06: Jazz Pharmaceuticals Announces Data From Phase 3 JZP-110 Study, Shows Statistically Significant Effects Of Both Doses On Co-Primary Endpoints

Financial news for JAZZ dated on 2017-05-31: Jazz Pharmaceuticals Announces FDA Acceptance Of NDA For VYXEOS

Financial news for JAZZ dated on 2017-05-24: Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected

Financial news for JAZZ dated on 2017-05-23: UBS Global Health Care Conference Continues Today, Presenters Include: Celgene, Jazz Pharma, Depomed, Walgreens, And Zymeworks

Financial news for JAZZ dated on 2017-05-15: Benzinga's Top Upgrades, Downgrades For May 15, 2017

Financial news for JAZZ dated on 2017-05-15: RBC Capital Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Top Pick Rating, Announces \$210.00 Price Target

Financial news for JAZZ dated on 2017-05-09: Jazz Pharmaceuticals Sees FY17 Sales \$1.625-\$1.70B vs \$1.67B Est., EPS \$10.70-\$11.30 vs \$11.12 Est.

Financial news for JAZZ dated on 2017-05-09: Jazz Pharmaceuticals REports Q1 Adj. EPS \$2.31 vs \$2.34 Est., Sales \$376M vs \$377M Est.

Financial news for JAZZ dated on 2017-05-09: Earnings Scheduled For May 9, 2017

Financial news for JAZZ dated on 2017-05-05: 4 Medical Stocks That Could Be Big Winners Next Week

Financial news for JAZZ dated on 2017-04-26: Jazz Pharma Announces 'Positive' Phase 3 TONES Results

Financial news for JAZZ dated on 2017-04-24: Jazz Pharmaceuticals Announces Phase 2/3 Express Study Of Xyrem, Demonstrated Significant Differences In Primary And Secondary Efficacy Endpoints

Financial news for JAZZ dated on 2017-04-06: 12 Biggest Mid-Day Gainers For Thursday

Financial news for JAZZ dated on 2017-04-06: UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma

Financial news for JAZZ dated on 2017-04-06: 7 Biggest Price Target Changes For Thursday

Financial news for JAZZ dated on 2017-04-06: Benzinga's Top Upgrades, Downgrades For April 6, 2017

Financial news for JAZZ dated on 2017-04-06: The Market In 5 Minutes

Financial news for JAZZ dated on 2017-04-06: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for JAZZ dated on 2017-04-06: Mizuho Downgrades Jazz Pharmaceuticals To Neutral, Lowers Price Target To \$150

Financial news for JAZZ dated on 2017-04-05: Jazz Pharma Reaches Settlement With Hikma Pharma Related To Xyrem Patent Case, Grants Hikma Right To Sell Authorized Generic Version Commencing Jan 1, 2023

Financial news for JAZZ dated on 2017-04-03: Jazz Pharmaceuticals Completes Rolling Submission of NDA for Vyxeos

Financial news for JAZZ dated on 2017-03-30: Jazz Pharmaceuticals, Nippon Shinyaku Enter Into License Agreements for Development, Commercialization of Defitelio, Vyxeos in Japan; Financial Terms Not Disclosed

Financial news for JAZZ dated on 2017-03-24: 'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market

Financial news for JAZZ dated on 2017-03-22: Jazz Pharma Shares Volatile Over Last Few Mins; Hearing Report Co. Has Lost Intellectual Property Rights Ruling Related to Xyrem Patent '963

Financial news for JAZZ dated on 2017-03-20: Jazz Pharma Gives Shorts A Wake-Up Call After JZP-110 Study Results

Financial news for JAZZ dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for JAZZ dated on 2017-03-20: UPDATE: Jazz Says 'Abstracts Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017'

Financial news for JAZZ dated on 2017-03-20: Jazz Pharma Reports Results from Phase 3 TONES 3, TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea

Financial news for JAZZ dated on 2017-03-17: Benzinga's Option Alert Recap From March 17

Financial news for JAZZ dated on 2017-03-17: Option Alert: Jazz Pharma Mar 31st 140 Calls: 650 @ ASK \$1.90: 650 traded vs 315 OI: Earnings 5/9 After Close (est) \$134.52 Ref

Financial news for JAZZ dated on 2017-03-15: Jazz Pharmaceuticals Reports First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258

Financial news for JAZZ dated on 2017-02-28: Jazz Pharma Sees FY17 Adj. EPS \$10.70-\$11.30 vs \$11.33 Est., Sales \$1.625B-\$1.7B vs \$1.68B Est.

Financial news for JAZZ dated on 2017-02-28: Jazz Pharmaceuticals Reports Q4 Adj. \$2.71 vs \$2.65 Est., Sales \$396.621M vs \$398.3M Est.

Financial news for JAZZ dated on 2017-02-28: Earnings Scheduled For February 28, 2017

Financial news for JAZZ dated on 2017-02-23: Vetr And Evercore Put Jazz Pharmaceuticals At Buy

Financial news for JAZZ dated on 2017-02-23: Benzinga's Top Upgrades, Downgrades For February 23, 2017

Financial news for JAZZ dated on 2017-02-23: Evercore ISI Group Initiates Coverage On Jazz Pharmaceuticals At Buy

Financial news for JAZZ dated on 2017-02-08: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Of JZP-110

Financial news for JAZZ dated on 2017-01-27: Traders Attributing Weakness In Jazz Pharma To Updated Xyrem Label Posted Today With New Warning On Additional Neuropsychiatric Reactions

Financial news for JAZZ dated on 2017-01-24: Jazz Pharma Weakness Being Attributed To FDA Warning Letter For Porton Bio

Financial news for JAZZ dated on 2017-01-18: Jazz Pharma To Evaluate If Generic Xyrem's FDA Waiver Meets Required Legal Conditions

Financial news for JAZZ dated on 2017-01-18: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for JAZZ dated on 2017-01-18: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JAZZ dated on 2017-01-18: Jazz Pharma Says Will Evaluate if FDA Waiver for Generic Xyrem Meets Legal Conditions Required

Financial news for JAZZ dated on 2017-01-17: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide

Financial news for JAZZ dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares at Overweight, Announces \$187.00 Target

Financial news for JAZZ dated on 2016-11-28: Jazz Pharmaceuticals Reports Completion Of Patient Enrollment For Phase 3 Study Of JZP-110

Financial news for JAZZ dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for JAZZ dated on 2016-11-09: The Market In 5 Minutes: Trump Victory Spooks Stocks

Financial news for JAZZ dated on 2016-11-09: A Peek Into The Markets: U.S. Stock Futures Tumble As Trump Wins 2016 Presidential Election

Financial news for JAZZ dated on 2016-11-09: Keep an Eye on These 10 Stocks for November 9, 2016

Financial news for JAZZ dated on 2016-11-08: Jazz Pharmaceuticals Sees FY16 Rev. \$1.485-\$1.53B vs. Est. \$1.51B, EPS \$9.90-\$10.30 vs. Est. \$10.05

Financial news for JAZZ dated on 2016-11-08: Jazz Pharmaceuticals Reports Q3 EPS \$2.57 vs. Est. \$2.61, Rev. \$374.181M vs. Est. \$388.88M

Financial news for JAZZ dated on 2016-11-08: Earnings Scheduled For November 8, 2016

Financial news for JAZZ dated on 2016-11-03: Jazz Pharma Shares Ticking Over \$102 Level as Hearing Cowen Making Mid-Day Comments on Name, Defending

Financial news for JAZZ dated on 2016-10-03: Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos Expects to Complete NDA Submission by Early 2017

Financial news for JAZZ dated on 2016-09-27: The Drug Price Increase Debate: Separating The Winners From The Losers

Financial news for JAZZ dated on 2016-09-26: Jazz Pharmaceuticals Reports That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea

Financial news for JAZZ dated on 2016-09-21: Next Year Setting Up To Be Smooth For Jazz Pharmaceuticals

Financial news for JAZZ dated on 2016-09-13: Shkreli Thinks The Mylan-Epipen Controversy Is 'Not Very Fair'

Financial news for JAZZ dated on 2016-09-12: Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth \$20 Billion, While Mast Therapeutics Is 'Worthless'

Financial news for JAZZ dated on 2016-09-12: Martin Shkreli Says He's Looking at Jazz Pharma, Suggesting He Likes the Stock, Says 'Looks Like it Could Be Worth Double the Stock Price'

Financial news for JAZZ dated on 2016-09-06: 5 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for JAZZ dated on 2016-09-01: Martin Shkreli @MartinShkreli Tweet: \$JAZZ appears to be worth double the current stock price

Financial news for JAZZ dated on 2016-08-27: Here Are All The Big Biotech Mergers In 2016

Financial news for JAZZ dated on 2016-08-25: Janney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise'

Financial news for JAZZ dated on 2016-08-25: Benzinga's Top Initiations

Financial news for JAZZ dated on 2016-08-25: Janney Capital Initiates Coverage on Jazz Pharmaceuticals at Neutral

Financial news for JAZZ dated on 2016-08-11: Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report

Financial news for JAZZ dated on 2016-08-10: Jazz Pharmaceuticals Remains On Goldman's Buy List

Financial news for JAZZ dated on 2016-08-09: 5 Stocks Shaken By Earnings In Tuesday's After-Hours Session

Financial news for JAZZ dated on 2016-08-09: Jazz Pharmaceuticals Misses Earnings, Cuts Guidance

Financial news for JAZZ dated on 2016-08-09: Jazz Pharma Reports Q2 EPS \$2.63 vs \$2.80 Est, Rev \$381.16M vs \$376.42M Est

Financial news for JAZZ dated on 2016-08-09: Earnings Scheduled For August 9, 2016

Financial news for JAZZ dated on 2016-08-03: Jazz Pharmaceuticals Announces US Centers for Medicare and Medicaid Services has Granted New Technology Add-on Payment for Defitelio; NTAP Payment for Defitelio has been Established at \$75,900

Financial news for JAZZ dated on 2016-07-28: Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies

Financial news for JAZZ dated on 2016-07-28: Cowen Says End Of Uncertainty Is Nearing For IPR Decision On Xyrem, Should Be Value Creating; Continue To Add Shares

Financial news for JAZZ dated on 2016-07-28: Traders Attributing Spike in Jazz Due to Favorable Patent Ruling Involving Xyrem

Financial news for JAZZ dated on 2016-07-28: Jazz Pharmaceuticals Spiking Higher

Financial news for JAZZ dated on 2016-07-28: Jazz Spikes to High of \$142.86 on Volume

Financial news for JAZZ dated on 2016-07-22: What Is An Options Sweep?

Financial news for JAZZ dated on 2016-07-22: Watch These 7 Huge Call Purchases In Friday Trade

Financial news for JAZZ dated on 2016-07-21: Jazz Pharma Spikes to High of \$145.55 on

Vol

Financial news for JAZZ dated on 2016-07-21: Option Alert: JAZZ Aug16 146 Calls Sweep: 676 @ ASK \$6.20: 676 traded vs 0 OI: Earnings 8/3 \$144.51 Ref

Financial news for JAZZ dated on 2016-07-12: Jazz Pharmaceuticals Announces Results of Tender Offer for Celator Pharmaceuticals Shares

Financial news for JAZZ dated on 2016-06-30: Celator Pharmaceuticals Announces Putative Class-action Lawsuit Challenging Acquisition by Jazz Pharmaceuticals

Financial news for JAZZ dated on 2016-06-29: BMO Sees Jazz Pharma As 'A Rare Breed In Specialty Pharma'

Financial news for JAZZ dated on 2016-06-29: BMO Capital Initiates Coverage on Jazz Pharmaceuticals at Outperform

Financial news for JAZZ dated on 2016-06-27: Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals Acquisition

Financial news for JAZZ dated on 2016-06-14: Jazz Pharma Says New Data on JZP-110 Showed Each Doses Had Consistently Lower Ratings on Primary Endpoint of Peak Liking at the Moment, Secondary Endpoints of Overall Drug Liking, Willingness to Take

Financial news for JAZZ dated on 2016-06-06: Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'

Financial news for JAZZ dated on 2016-06-06: Goldman Sees 26% Upside In Jazz Pharma Shares

Financial news for JAZZ dated on 2016-06-06: Benzinga's Top Initiations

Financial news for JAZZ dated on 2016-06-06: Goldman Sachs Initiates Coverage on Jazz Pharmaceuticals at Buy, Announces \$196.00 PT

Financial news for JAZZ dated on 2016-06-02: SunTrust On Jazz's Celator Purchase: 'Makes Strategic, Financial Sense'

Financial news for JAZZ dated on 2016-06-01: 8 Mergers You Might Have Missed On Tuesday

Financial news for JAZZ dated on 2016-05-31: Mid-Afternoon Market Update: Dow Drops 125 Points; Cliffs Natural Resources Shares Spike Higher

Financial news for JAZZ dated on 2016-05-31: Mid-Day Market Update: Dow Falls Over 50 Points; Celator Pharmaceuticals Shares Jump After Acquisition Announcement By Jazz Pharmaceuticals

Financial news for JAZZ dated on 2016-05-31: Benzinga's Volume Movers

Financial news for JAZZ dated on 2016-05-31: Stocks Hitting 52-Week Highs

Financial news for JAZZ dated on 2016-05-31: Mid-Morning Market Update: Markets Edge Higher; Medtronic Earnings Top Views

Financial news for JAZZ dated on 2016-05-31: Today's Top 10 Pre-Market Gainers

Financial news for JAZZ dated on 2016-05-31: The Market In 5 Minutes: Welcome Back

Financial news for JAZZ dated on 2016-05-31: Celator Surges 70% After Acquisition Announcement By Jazz Pharmaceuticals

Financial news for JAZZ dated on 2016-05-31: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for JAZZ dated on 2016-05-31: Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals for \$30.25/Share in Cash

Financial news for JAZZ dated on 2016-05-20: How Big Pharma Uses Charity Programs To Cover Drug Price Hikes

Financial news for JAZZ dated on 2016-05-17: Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December

Financial news for JAZZ dated on 2016-05-11: The Market In 5 Minutes: Don't Stop Me Now

Financial news for JAZZ dated on 2016-05-10: Jazz Pharma Sees EPS \$11.10-\$11.50 Vs Est \$11.14, Sales \$1.490B-\$1.550B Vs Est \$1.53B

Financial news for JAZZ dated on 2016-05-10: Jazz Pharma Reports Adj EPS \$2.26 Vs Est \$2.31, Sales \$336M Vs Est \$338.86M

Financial news for JAZZ dated on 2016-05-10: Earnings Scheduled For May 10, 2016

Financial news for JAZZ dated on 2016-04-25: The Market In 5 Minutes: Monday, April 25, 2016

Financial news for JAZZ dated on 2016-04-25: Benzinga's Top Upgrades

Financial news for JAZZ dated on 2016-04-25: SunTrust Robinson Humphrey Upgrades Jazz Pharmaceuticals to Buy, Raises PT to \$200.00

Financial news for JAZZ dated on 2016-04-13: Jazz Pharma Investors: Did You Catch This Favorable Ruling?

Financial news for JAZZ dated on 2016-04-13: Benzinga's Volume Movers

Financial news for JAZZ dated on 2016-04-08: Fast Money Picks For April 8: Buy KB Home, Short The Russell 2000

Financial news for JAZZ dated on 2016-03-31: What Does Jazz Pharma's Latest FDA Approval Mean?

Financial news for JAZZ dated on 2016-03-30: UPDATE: Jazz Pharmaceuticals Announces Webcast for Defitelio Investor Update

Financial news for JAZZ dated on 2016-03-30: UPDATE: Jazz Pharmaceuticals Defitelio Is First, Only FDA-Approved Therapy For Patients With This Rare Complication

Financial news for JAZZ dated on 2016-03-30: Jazz Pharma Announces FDA Approval of Defitelio

Financial news for JAZZ dated on 2016-03-30: Shares of Jazz Pharma Spike Higher as Hearing FDA Has Approved First Treatment for Rare Disease in Patients Who Received Stem Cell Transplant from Blood, Bone Marrow

Financial news for JAZZ dated on 2016-03-23: What's Going On With Kyle Bass And Biogen?

Financial news for JAZZ dated on 2016-02-24: Jazz Pharma Falls After Q4 Sales Miss Street View

Financial news for JAZZ dated on 2016-02-24: Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals, Lowers PT to \$200.00

Financial news for JAZZ dated on 2016-02-23: Earnings Recap For February 23

Financial news for JAZZ dated on 2016-02-23: Jazz Pharma Sees FY 2016 EPS \$10.90-\$11.30 Vs Est \$11.42 & Sales \$1.49B-\$1.55B Vs Est \$1.54B

Financial news for JAZZ dated on 2016-02-23: Jazz Pharmaceuticals Reports Q4 EPS \$2.60 vs. Est. \$2.60, Rev. \$340.881M vs. Est. \$349M

Financial news for JAZZ dated on 2016-02-23: Earnings Scheduled For February 23, 2016

Financial news for JAZZ dated on 2016-02-19: Wells Fargo Initiates Coverage on Jazz Pharmaceuticals at Outperform

Financial news for JAZZ dated on 2016-02-12: Patrick Enright Sells 10,000 Shares Of Jazz Pharmaceutical @\$117.92/Share -Form 4

Financial news for JAZZ dated on 2016-02-01: UPDATE: Jazz Pharma Phase 3 Trial Result for Defibrotide Show Improved Survival, Complete Response Compared with Historical Controls

Financial news for JAZZ dated on 2016-02-01: Jazz Pharmaceuticals Phase 3 Defibrotide Trial Published Online In BLOOD

Financial news for JAZZ dated on 2016-01-20: Over 1,000 Stocks On The NYSE Just Hit 52-Week Lows

Financial news for JAZZ dated on 2016-01-14: 3 Stocks To Watch In Thursday's After-Hours Session

Financial news for JAZZ dated on 2016-01-02: Kyle Bass Explains The 'Patent Trolls' Situation In The Pharma Industry

Financial news for JAZZ dated on 2015-12-17: Martin Shkreli-KaloBios Saga An Example Of How Penny Stocks Can Be Misunderstood, Tim Sykes Says

Financial news for JAZZ dated on 2015-11-25: Bernstein Initiates Coverage on Jazz Pharmaceuticals at Market Perform, Announces \$160.00 PT

Financial news for JAZZ dated on 2015-11-10: Benzinga's Top Downgrades

Financial news for JAZZ dated on 2015-11-10: Mizuho Securities Downgrades Jazz Pharmaceuticals to Neutral, Lowers PT to \$140.00

Financial news for JAZZ dated on 2015-11-09: Jazz Pharma Sees FY15 Adj. EPS \$9.45-\$9.60 vs \$9.67 Est., Sales \$1.32B-\$1.34B vs \$1.36B est.

Financial news for JAZZ dated on 2015-11-09: Jazz Pharma Reports Q3 Adj. EPS \$2.52 vs \$2.56 Est., Sales \$341M vs \$348M Est.

Financial news for JAZZ dated on 2015-11-09: Earnings Scheduled For November 9, 2015

Financial news for JAZZ dated on 2015-11-05: 2 Hot Upcoming Healthcare Earnings Calls

Financial news for JAZZ dated on 2015-10-15: Hearing Jazz Pharma Intellectual Property Right Decision Is Positive

Financial news for JAZZ dated on 2015-10-14: Northland Starts Jazz Pharma, Mallinckrodt, Shire With Outperform Ratings

Financial news for JAZZ dated on 2015-10-14: Northland Securities Initiates Coverage on Jazz Pharmaceuticals at Outperform, Announces \$200.00 PT

Financial news for JAZZ dated on 2015-10-09: How To Invest During Biotech's Latest Crisis

Financial news for JAZZ dated on 2015-10-08: Mizuho Securities Initiates Coverage on Jazz Pharmaceuticals at Buy, Announces \$164.00 PT

Financial news for JAZZ dated on 2015-10-05: Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You

Financial news for JAZZ dated on 2015-09-30: Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease

Financial news for JAZZ dated on 2015-08-05: Jazz Pharma Reports Q1 EPS \$2.41 Vs Est \$2.41, Sales \$333.7M Vs Est \$335.36M

Financial news for JAZZ dated on 2015-07-31: The Wall Street Research Making Waves Today

Financial news for JAZZ dated on 2015-07-31: Jazz Pharma Could Be Worth Over \$200 If Xyrem Adds Long-Term Value: Here's How

Financial news for JAZZ dated on 2015-07-28: ETFs For The Next Pharma Takeover Candidates

Financial news for JAZZ dated on 2015-07-15: Earning & Economic Calendar for Wednesday July 15, 2015

Financial news for JAZZ dated on 2015-07-09: Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz

Financial news for JAZZ dated on 2015-06-29: Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To \$210

Financial news for JAZZ dated on 2015-06-09: Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic

Financial news for JAZZ dated on 2015-06-08: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110

Financial news for JAZZ dated on 2015-06-04: Jazz Pharma. To Present Abstracts from Ongoing Evaluations of Xyrem at SLEEP 2015

Financial news for JAZZ dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for JAZZ dated on 2015-05-27: 8-K from Ampio Pharma Shows Co. Has Purchased Jazz Pharma's ProstaScint for \$1M at Closing Plus Added \$500K Payable Within Five Days After Transfer

Financial news for JAZZ dated on 2015-05-07: Jazz Pharma Reports Q1 EPS \$1.99 Vs Est \$2.14, Sales \$309.3M Vs Est \$308.29M

Financial news for JAZZ dated on 2015-05-07: High Expectations For Jazz Pharmaceuticals

Financial news for JAZZ dated on 2015-05-07: Earning & Economic Calendar for Thursday May 7, 2015

Financial news for JAZZ dated on 2015-05-07: Earnings Scheduled For May 7, 2015

Financial news for JAZZ dated on 2015-04-27: Oppenheimer Analysts Pick A Top Stock From Each Market Sector

Financial news for JAZZ dated on 2015-04-20: Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent

Financial news for JAZZ dated on 2015-04-18: Why This Trader Is Worried About Jazz Pharmaceuticals

Financial news for JAZZ dated on 2015-04-08: How Much Further Can Jazz Pharmaceuticals Fall?

Financial news for JAZZ dated on 2015-04-07: Bass Challenges Jazz Pharmaceuticals Patent for Xyrem -DJ

Financial news for JAZZ dated on 2015-03-30: Shares of Shire, Jazz Pharma Quiet Following Bloomberg Headlines Suggesting Sigma-Tau's Rare Diseases Unit Could Draw Interest

Financial news for JAZZ dated on 2015-03-18: Oppenheimer: Bullish Technical Analysis Of 5 Healthcare Names

Financial news for JAZZ dated on 2015-03-02: Jazz Pharmaceuticals Says on February 27, 2015, FDA Notified Co's Unit of Approval of Risk Evaluation and Mitigation Strategy for Xyrem, FDA Concluded Xyrem REMS Meets Applicable Statutory Standards

Financial news for JAZZ dated on 2015-02-25: Heavy News Day For Several Biotech Stocks

Financial news for JAZZ dated on 2015-02-25: 8 Stories JP Morgan Is Watching Today

Financial news for JAZZ dated on 2015-02-25: Benzinga's Top #PreMarket Losers

Financial news for JAZZ dated on 2015-02-24: Jazz Pharmaceuticals Sinks On Outlook, Halt In Drug Trial

Financial news for JAZZ dated on 2015-02-24: Jazz Pharmaceuticals Reports jeffrey Tobias, Executive VP of R&D, Chief Medical Officer, to Retire

Financial news for JAZZ dated on 2015-02-24: Jazz Pharma Reports Q4 EPS \$2.44 Vs Est \$2.31, Sales \$328.1M Vs Est \$320.27M

Financial news for JAZZ dated on 2015-02-20: Benzinga's Top Initiations

Financial news for JAZZ dated on 2015-02-20: BMO Capital Initiates Jazz Pharmaceuticals At Outperform

Financial news for JAZZ dated on 2015-02-20: BMO Capital Initiates Coverage on Jazz Pharmaceuticals at Outperform, Announces \$200.00 PT

Financial news for JAZZ dated on 2015-02-19: Stifel: Now's The Time To Buy These 3 Stocks

Financial news for JAZZ dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for JAZZ dated on 2015-01-07: Jazz Pharmaceuticals Director Enright Sells 10,000 Shares @\$160.25/Share -Form 4

Financial news for JAZZ dated on 2014-12-11: Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide

Financial news for JAZZ dated on 2014-12-09: Jazz Pharma, Concert Pharma Report JZP-386 Program Update

Financial news for JAZZ dated on 2014-12-03: Great News For Biogen, But What's Next For The Stock?

Financial news for JAZZ dated on 2014-12-02: Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease At ASH

Financial news for JAZZ dated on 2014-12-02: Jazz Pharmaceuticals Announces First Patients Enrolled In Phase 3 Trial Of Xyrem

Financial news for JAZZ dated on 2014-11-20: Riding The Bull Market With These 2 Momentum ETFs

Financial news for JAZZ dated on 2014-11-05: This Biotech's Earnings Are Sending It Toward New Highs

Financial news for JAZZ dated on 2014-11-04: Jazz Pharmaceuticals plc Sees FY2014 EPS \$8.20-8.35 vs \$8.17 Est; Sees Sales \$1.15M-1.17M

Financial news for JAZZ dated on 2014-11-04: Jazz Pharmaceuticals plc Reports Q3 EPS of \$2.33 vs \$2.22 Est; Revenue of \$306.58M vs \$302.48M Est

Financial news for JAZZ dated on 2014-11-04: Earnings Scheduled For November 4, 2014

Financial news for JAZZ dated on 2014-10-08: Jazz Pharmaceuticals Director Enright Sells 10,000 Shares @\$160.56/Share -Form 4

Financial news for JAZZ dated on 2014-09-16: Jazz Pharma Shares Move Lower; May be Attributed to Article from Irish Times: 'OECD plan likely to prompt changes to Irish corporate tax regime'

Financial news for JAZZ dated on 2014-09-05: Jazz Pharmaceuticals Up On Allergan, Inc. Rumor

Financial news for JAZZ dated on 2014-09-05: Hearing Deal Reporter Says Jazz Takeover Target of Allergan

Financial news for JAZZ dated on 2014-08-19: Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs

Financial news for JAZZ dated on 2014-08-19: JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

Financial news for JAZZ dated on 2014-08-19: UPDATE: Valeant, Jazz Shares Move Higher on WSJ Report of Potential Allergan Deal for Salix

Financial news for JAZZ dated on 2014-08-19: Jazz Pharma Shares Continue Higher for Fifth Session in a Row; JP Morgan Earlier Initiated Coverage with Overweight Rating

Financial news for JAZZ dated on 2014-08-06: Jazz Pharma Announces \$500M Note Offering

Financial news for JAZZ dated on 2014-08-06: Morning Market Movers

Financial news for JAZZ dated on 2014-08-06: Jazz Pharmaceuticals Spikes In #PreMarket On Q2 Beat; Boosts Revenue Outlook

Financial news for JAZZ dated on 2014-08-06: Benzinga's Top #PreMarket Gainers

Financial news for JAZZ dated on 2014-08-05: Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower

Financial news for JAZZ dated on 2014-07-23: Benzinga's Top Initiations

Financial news for JAZZ dated on 2014-07-23: Buckingham Research Initiates Jazz Pharmaceuticals With Buy

Financial news for JAZZ dated on 2014-07-23: Buckingham Research Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$215.00 PT

Financial news for JAZZ dated on 2014-07-16: SunTrust Robinson Humphrey Initiates Coverage on Jazz Pharmaceuticals plc at Neutral, Announces \$158.00 PT

Financial news for JAZZ dated on 2014-07-08: Jazz Pharmaceuticals Receives Patent Entitled 'Method of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transporters' -8-K

Financial news for JAZZ dated on 2014-07-02: Jazz Pharma Reports Deal to Buy Rights to Defibrotide, Sigma-Tau Will Get Upfront Payment \$75M, Milestone Payments \$25M, Could Also Get Up to Added \$150M Based on Timing

Financial news for JAZZ dated on 2014-06-16: Cramer Says Eaton, TE Connectivity, Pentair, Tyco, Alkermes, Jazz Pharma, Weatherford May be Takeover Targets, Similar

Situations to Covidien Regarding Tax Benefit

Financial news for JAZZ dated on 2014-06-11: Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss

Financial news for JAZZ dated on 2014-06-11: Wells Fargo Initiates Coverage On The Pharmaceutical Space

Financial news for JAZZ dated on 2014-06-11: Wells Fargo Initiates Coverage on Jazz Pharmaceuticals plc at Outperform

Financial news for JAZZ dated on 2014-06-02: UPDATE: Jazz Said Both Primary, Secondary Endpoints Met in Phase 2b Trial of JZP-110

Financial news for JAZZ dated on 2014-06-02: Jazz Pharma Presented Phase 2b Data for JZP-110 for Treatment of EDS Systems in Adults with Narcolepsy

Financial news for JAZZ dated on 2014-06-02: UPDATE: Jazz Pharma Release Shows All Primary/Secondary Endpoints Were Met in Study, JZP-110 Was Generally Well Tolerated

Financial news for JAZZ dated on 2014-06-02: Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy

Financial news for JAZZ dated on 2014-05-27: Market Wrap For May 27: S&P 500 Closes At New Record High After Holiday Weekend

Financial news for JAZZ dated on 2014-05-19: Jazz Pharmaceuticals Announces Russell Cox COO

Financial news for JAZZ dated on 2014-05-15: 13F Filing from Stephen Mandel's Lone Pine Shows New Stakes in Actavis, Adobe, Jazz Pharma, Liquidated Positions in AmEx, Mead Johnson, Dollar Tree, Kinder Morgan

Financial news for JAZZ dated on 2014-05-14: Five Star Biotech Stock Watch: Jazz Pharmaceuticals

Financial news for JAZZ dated on 2014-05-08: Jazz Pharmaceuticals plc Sees FY2014 EPS \$8.00-8.25 vs \$8.20 Est; Sees Sales \$1.10B-1.16B vs \$1.13B Est

Financial news for JAZZ dated on 2014-05-08: Jazz Pharmaceuticals plc Reports Q1 EPS of \$1.61 vs \$1.79 Est; Revenue of \$246.90M vs \$254.86M Est

Financial news for JAZZ dated on 2014-04-17: Market Wrap For April 17: Mixed Earnings Drag The Dow Lower While S&P 500 & Nasdaq End Positive

Financial news for JAZZ dated on 2014-04-17: Benzinga's Top Initiations

Financial news for JAZZ dated on 2014-04-17: Canaccord Genuity Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$163.00 PT

Financial news for JAZZ dated on 2014-03-31: Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy

Financial news for JAZZ dated on 2014-03-31: UPDATE: Jazz Pharmaceuticals, Gentium Announce European Commercial Launch of Defitelio

Financial news for JAZZ dated on 2014-03-31: Jazz Pharmaceuticals, Gentium Announce European Commercial Launch of First Approved Life-Saving Treatment for Severe Hepatic Veno-Occlusive Disease

Financial news for JAZZ dated on 2014-03-28: UPDATE: Ariad Pharmaceuticals Shares Rise 5% Premarket Following Thursday's UK Daily Mail Report of Rumored \$20 Bid from Jazz Pharmaceuticals

Financial news for JAZZ dated on 2014-03-27: Daily Mail Reports Jazz Pharmaceuticals Willing to Pay \$20/Share for Ariad

Financial news for JAZZ dated on 2014-03-07: Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains

Financial news for JAZZ dated on 2014-03-07: Barclays Reinstates Overweight on Jazz Pharmaceuticals plc, Announces \$200.00 PT

Financial news for JAZZ dated on 2014-03-06: Form 8-K from Jazz Pharma Shows Court Issued Order on March 5th Granting a Stay of Claims Related to '730 Patent Family

Financial news for JAZZ dated on 2014-02-28: Jazz Reports Two Investors Exercised 947,867 Warrants for Shares

Financial news for JAZZ dated on 2014-02-26: Morning Movers for Feb. 26, 2014: ANIK, JAKK, ZAGG, PLUG, TASR, ANF Moving Higher, FST, UTIW, SEAC, FSLR, DWA Lower

Financial news for JAZZ dated on 2014-02-26: Cantor Fitzgerald Downgrades Jazz Pharmaceuticals plc to Hold, Raises PT to \$182.00

Financial news for JAZZ dated on 2014-02-26: Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals plc, Raises PT to \$195.00

Financial news for JAZZ dated on 2014-02-25: Jazz Pharma Posts 12% Increase in Q4 Profit, But Still Misses; Guides Above the Street

Financial news for JAZZ dated on 2014-02-25: UPDATE: Jazz Pharmaceuticals Shares Fall 4% After-Hours on Earnings Miss

Financial news for JAZZ dated on 2014-02-25: Jazz Pharma Says CFO Stepping Down, Names Matthew Young as Replacement

Financial news for JAZZ dated on 2014-02-25: Jazz Pharmaceuticals plc Sees FY2014 EPS \$8.00-8.25 vs \$8.07 Est; Sees Sales \$1.09B-1.15B vs \$1.08B Est

Financial news for JAZZ dated on 2014-02-25: Jazz Pharmaceuticals plc Reports Q4 EPS of \$1.72 vs \$1.78 Est; Revenue of \$235.80M vs \$238.12M Est

Financial news for JAZZ dated on 2014-02-25: Earning and Economic Calendar for Tuesday February 25 2014

Financial news for JAZZ dated on 2014-02-25: Earnings Scheduled For February 25, 2014

Financial news for JAZZ dated on 2014-02-12: Option Alert: Jazz Pharmaceutical June \$175 Call; 1,751 Contracts Traded vs 148 OI; Currently \$163.48

Financial news for JAZZ dated on 2014-01-15: Gentium Holders Sue to Stop Jazz Pharma Purchase

Financial news for JAZZ dated on 2014-01-14: Form 8-K from Jazz Pharma Shows Reaffirmed Outlook

Financial news for JAZZ dated on 2014-01-13: Jazz Announces Acquisition of Rights to ADX-N05 from Aerial Biopharma for \$125M Upfront Payment

Financial news for JAZZ dated on 2014-01-02: Market Wrap For January 2: Markets Begin 2014 on Negative Note

Financial news for JAZZ dated on 2013-12-20: Market Wrap For December 20: Markets Gain On GDP Data

Financial news for JAZZ dated on 2013-12-20: Mid-Afternoon Market Update: Textron Rises as Markets Rise Across the Board

Financial news for JAZZ dated on 2013-12-20: Mid-Day Market Update: Red Hat Surges On Upbeat Results; CarMax Shares Decline

Financial news for JAZZ dated on 2013-12-20: Mid-Morning Market Update: Markets Rally; BlackBerry Posts Q3 Loss

Financial news for JAZZ dated on 2013-12-20: ETF Outlook for Friday, December 20 (REM, USO, IBB, FCG)

Financial news for JAZZ dated on 2013-12-19: Benzinga's M&A Chatter for Thursday December 19, 2013

Financial news for JAZZ dated on 2013-12-19: PREVIEW: Gentium to Resume Trading at 5:15 PM ET

Financial news for JAZZ dated on 2013-12-19: Jazz Pharmaceuticals Trading at \$118 Following Announcement of Gentium Acquisition

Financial news for JAZZ dated on 2013-12-19: Jazz Pharmaceuticals to Acquire Gentium for \$57.00/Share

Financial news for JAZZ dated on 2013-12-16: Market Wrap For December 16: Dow Posts Triple Point Gain Ahead of Fed Meeting

Financial news for JAZZ dated on 2013-12-16: Goldman Sachs Downgrades Jazz Pharmaceuticals plc to Neutral, Raises PT to \$123.00

Financial news for JAZZ dated on 2013-12-04: Cantor Fitzgerald Boosts Price Target on Jazz Pharma from \$106 to \$145, Maintains Buy

Financial news for JAZZ dated on 2013-11-25: Market Wrap For November 25: Nasdaq Breaks 4,000 Level For First Time Since 2000

Financial news for JAZZ dated on 2013-11-13: RF Lafferty Lifts Target on Jazz Pharma from \$102 to \$118, Maintains Buy

Financial news for JAZZ dated on 2013-11-11: Jazz Pharmaceuticals Crosses Above \$100

Financial news for JAZZ dated on 2013-11-05: Jazz Pharmaceuticals plc Sees FY2013 EPS \$6.30-6.40 vs \$6.30 Est; Sees Sales \$867.0M-877.0M vs \$872.10M Est

Financial news for JAZZ dated on 2013-11-05: Jazz Pharmaceuticals plc Sees FY2013 EPS \$6.30-6.40 vs \$6.30 Est; Sees Sales \$867.0M-877.0M vs \$872.90M Est

Financial news for JAZZ dated on 2013-11-05: Jazz Pharmaceuticals plc Reports Q3 EPS of \$1.78 vs \$1.67 Est; Revenue of \$232.20M vs \$227.38M Est

Financial news for JAZZ dated on 2013-11-05: Earnings Scheduled For November 5, 2013

Financial news for JAZZ dated on 2013-10-02: 5 Healthcare Stocks With The Highest EPS Estimates For The Next Quarter

Financial news for JAZZ dated on 2013-09-17: Goldman Sachs Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$105.00 PT

Financial news for JAZZ dated on 2013-08-13: Option Alert: Jazz Pharmaceuticals September 60 Put; Block Trade: 2,000 Contracts @\$0.10; Currently \$81.68

Financial news for JAZZ dated on 2013-08-07: UPDATE: Stifel Nicolaus Raises PT on Jazz Pharmaceuticals Following 2Q13 Revenue Report

Financial news for JAZZ dated on 2013-08-06: Jazz Pharmaceuticals plc Reports Q2 EPS of \$1.43 vs \$1.52 Est

Financial news for JAZZ dated on 2013-07-09: Cantor Fitzgerald Reiterates Jazz Pharmaceuticals at Buy on Favorable FDA Developments

Financial news for JAZZ dated on 2013-05-31: UPDATE: Stifel Nicolaus Initiates Jazz Pharmaceuticals at Buy on Multiple Positive Factors

Financial news for JAZZ dated on 2013-05-31: Stifel Nicolaus Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$80.00 PT

Financial news for JAZZ dated on 2013-05-31: Stifel Nicolaus Initiates Coverage on Jazz Pharmaceuticals plc at Buy

Financial news for JAZZ dated on 2013-05-22: Guggenheim Suggesting Jazz Pharma Could be Acquisition Target

Financial news for JAZZ dated on 2013-05-15: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Financial news for JAZZ dated on 2013-05-07: Jazz Pharmaceuticals plc Raises FY2013 EPS Guidance from \$5.70-5.90 to \$6.10-6.30 vs \$5.88 Est; Sees Sales \$823.0M-853.0M vs \$825.50M Est

Financial news for JAZZ dated on 2013-05-07: Jazz Pharmaceuticals Announces \$200M Buyback

Financial news for JAZZ dated on 2013-05-07: Jazz Pharmaceuticals plc Reports Q1 EPS of \$1.37 vs \$1.35 Est

Financial news for JAZZ dated on 2013-05-07: Earnings Scheduled For May 7, 2013

Financial news for JAZZ dated on 2013-03-28: JMP Securities Initiates Coverage on Jazz Pharmaceuticals plc at Market Outperform, Announces \$66.00 PT

Financial news for JAZZ dated on 2013-03-12: Citigroup Maintains Buy on Jazz Pharmaceuticals plc, Raises PT to \$75.00

Financial news for JAZZ dated on 2013-03-11: UPDATE: Cantor Fitzgerald Initiates Jazz Pharmaceuticals at Buy on Xyrem Outlook

Financial news for JAZZ dated on 2013-03-11: Benzinga's Top Initiations

Financial news for JAZZ dated on 2013-03-11: Cantor Fitzgerald Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$86.00 PT

Financial news for JAZZ dated on 2013-03-05: Jazz Pharma Prices 5.375M Shares at \$58.50/Share

Financial news for JAZZ dated on 2013-03-04: Jazz Announces 5.375M Share Secondary Offering

Financial news for JAZZ dated on 2013-02-27: UPDATE: Piper Jaffray Raises PT to \$69 on Jazz Pharmaceuticals; Growth Visibility is Solid

Financial news for JAZZ dated on 2013-02-27: Piper Jaffray Maintains Overweight on Jazz Pharmaceuticals plc, Raises PT to \$69.00

Financial news for JAZZ dated on 2013-02-26: Jazz Pharmaceuticals plc Sees FY2013 EPS \$5.70-5.90 vs \$5.67 Est; Sees Sales \$805.0M-835.0M vs \$811.30M Est

Financial news for JAZZ dated on 2013-02-26: Jazz Pharmaceuticals plc Reports Q4 EPS of \$1.53 vs \$1.42 Est

Financial news for JAZZ dated on 2013-02-26: Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Financial news for JAZZ dated on 2013-02-26: Earnings Scheduled For February 26, 2013

Financial news for JAZZ dated on 2013-02-25: Jazz Spikes Higher on Bank of America Initiation at Buy and \$74 PT

Financial news for JAZZ dated on 2013-02-25: Bank of America Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$74.00 PO

Financial news for JAZZ dated on 2012-12-17: Jazz Pharma Issues Warning Against Using Xyrem with Alcohol, Drugs Which Cause Respiratory Depression

Financial news for JAZZ dated on 2012-12-13: Jazz Pharma Says FDA Denied July Citizens Petition Filed on Requirements for Xyrem ANDA; Co. Evaluating Further Actions

Financial news for JAZZ dated on 2012-12-10: Jazz Pharmaceuticals Presents Data from Safety Trial of Patients Treated with Erwinaze

Financial news for JAZZ dated on 2012-12-04: Jazz Pharmaceuticals Announces Issuance of Additional Xyrem Patent

Financial news for JAZZ dated on 2012-12-04: Jazz Pharma Reports Issuance of Added Xyrem Patent

Financial news for JAZZ dated on 2012-12-03: Jazz Pharma Begins Trial of IV Administered Erwinaze

Financial news for JAZZ dated on 2012-11-29: UBS Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces \$64.00 PT

Financial news for JAZZ dated on 2012-11-27: UPDATE: Citigroup Initiates Jazz Pharmaceuticals at Buy; Expecting Settlement to Remove Overhang

Financial news for JAZZ dated on 2012-11-27: Benzinga's Top Initiations

Financial news for JAZZ dated on 2012-11-27: Citigroup Initiates Coverage Jazz Pharmaceuticals at Buy, Announces PT of \$70.00

Financial news for JAZZ dated on 2012-11-08: UPDATE: Jazz Pharma Guides FY EPS \$4.65-4.75 vs \$4.78 Est, sales \$575-585M vs \$611.1M Est

Financial news for JAZZ dated on 2012-11-08: Jazz Pharmaceuticals Reports Q3 EPS \$1.29 vs \$1.32 Est; Revenues \$176.0M vs \$179.62M Est

Financial news for JAZZ dated on 2012-10-15: Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda For \$95M

Financial news for JAZZ dated on 2012-10-12: Barclays Maintains Jazz Pharmaceuticals at Overweight, Raises PT from \$60 to \$70

Financial news for JAZZ dated on 2012-09-27: Brean Murray Carret Initiated Coverage on Jazz Pharmaceuticals at Buy, Announced PT to \$81

Financial news for JAZZ dated on 2012-09-18: Guggenheim Initiates Coverage Jazz Pharmaceuticals at Buy, Announces PT of \$60

Financial news for JAZZ dated on 2012-09-18: Jazz Pharma Says Ruling Generally Favorable to Its Positions, Received Markman Ruling September 17

Financial news for JAZZ dated on 2012-09-17: Jazz Pharma Continues its Rally, Up 15.34%

Financial news for JAZZ dated on 2012-09-17: Jazz Pharma Rallies Up 11%, Markman Ruling Against Rozane Posted on Friday

Financial news for JAZZ dated on 2012-09-11: Jazz Pharmaceuticals Rises 8% on Patent News, Cowen Upgrade

Financial news for JAZZ dated on 2012-09-11: Cowen Upgrades Jazz Pharmaceuticals to Outperform

Financial news for JAZZ dated on 2012-09-11: Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem(r)

Financial news for JAZZ dated on 2012-09-06: Jazz Pharmaceuticals Sells Women's Health Business

Financial news for JAZZ dated on 2012-09-06: A Peek Into The Market Before The Trading Starts

Financial news for JAZZ dated on 2012-09-06: Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Women's Health Business to Meda

Financial news for JAZZ dated on 2012-09-04: Hearing Navellier Sell on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2012-08-08: UPDATE: Piper Jaffray Raises PT on Jazz Pharmaceuticals from \$64 to \$68

Financial news for JAZZ dated on 2012-08-08: Piper Jaffray Maintains Jazz Pharmaceuticals at Overweight, Raises PT from \$64 to \$68

Financial news for JAZZ dated on 2012-08-07: Jazz Pharmaceuticals Reports Q2 EPS \$1.09 vs \$1.05 Est; Revenues \$129.5 vs \$125.53M Est

Financial news for JAZZ dated on 2012-06-19: Jazz Pharmaceuticals Could See FDA Reinspection -FT

Financial news for JAZZ dated on 2012-06-18: 5 Healthcare Stocks With The Highest Operating Margin

Financial news for JAZZ dated on 2012-05-23: UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, \$65 PT; Organic and Acquisition Growth Outlook

Financial news for JAZZ dated on 2012-05-23: Oppenheimer Initiates Coverage on Jazz Pharmaceuticals at Outperform, Announces PT of \$66

Financial news for JAZZ dated on 2012-05-09: Jazz Pharmaceuticals Down 4.5% on Weak 2012 Guidance

Financial news for JAZZ dated on 2012-05-08: Jazz Pharmaceuticals Reports Q1 EPS \$0.91 vs \$0.84 Est; Revenues \$108.4M vs \$102.48M Est

Financial news for JAZZ dated on 2012-04-27: Jazz Pharmaceuticals Rises 16% Pre-Market on EUSA Acquisition (\$52.40)

Financial news for JAZZ dated on 2012-04-27: Jefferies & Company Maintains Jazz Pharmaceuticals at Buy, Raises PT from \$64 to \$74

Financial news for JAZZ dated on 2012-04-26: Benzinga's M&A Chatter for Thursday April 26, 2012

Financial news for JAZZ dated on 2012-04-26: Jazz Pharmaceuticals Rises 6% After-Hours on EUSA Acquisition

Financial news for JAZZ dated on 2012-04-26: Jazz Pharmaceuticals to Acquire EUSA Pharma for \$650M; Transaction Would Be Immediately Accretive to Jazz Pharmaceuticals' Adjusted EPS

Financial news for JAZZ dated on 2012-04-10: UPDATE: Citi Initiates Coverage on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2012-04-10: Citigroup Initiates Coverage on Jazz Pharmaceuticals at Buy, Announces PT of \$60

Financial news for JAZZ dated on 2012-03-14: Longitude No Longer Holds More Than 5% Stake in Jazz

Financial news for JAZZ dated on 2012-03-05: Jazz Pharma Says 7.88M Shares Being Sold by Holders, Company Will Not Receive Any Proceeds

Financial news for JAZZ dated on 2012-03-01: Jefferies & Company Maintains Jazz Pharmaceuticals at Buy, Raises PT from \$64 to \$56

Financial news for JAZZ dated on 2012-02-29: Jazz Pharmaceuticals Trading 2.8% Higher on Heavy Volume; Currently at \$53.01

Financial news for JAZZ dated on 2012-02-28: UPDATE: Auriga Raises PT to \$57 on JAZZ Pharmaceuticals

Financial news for JAZZ dated on 2012-02-28: UPDATE: Piper Jaffray Raises Jazz Pharmaceuticals PT

Financial news for JAZZ dated on 2012-02-28: Auriga Maintains Jazz Pharmaceuticals at Buy, Raises PT from \$55 to \$57

Financial news for JAZZ dated on 2012-02-28: Piper Jaffray Maintains Jazz Pharmaceuticals at Overweight, Raises PT from \$61 to \$64

Financial news for JAZZ dated on 2012-02-27: Jazz Pharmaceuticals Adds 2% on Q4 Earnings Results

Financial news for JAZZ dated on 2012-02-27: Jazz Pharmaceuticals Reports Q4 EPS \$1.17 vs \$1.09 Est; Revenues \$83.5M vs \$80.84M Est

Financial news for JAZZ dated on 2012-02-17: Jazz Pharmaceuticals Spikes Lower on Heavy Volume; Currently at \$47.1

Financial news for JAZZ dated on 2012-02-08: Jazz Pharmaceuticals Hits 52-Week High of \$51.02

Financial news for JAZZ dated on 2012-02-06: Jazz Pharmaceuticals Hits 52-Week High of \$50.47

Financial news for JAZZ dated on 2012-02-06: Jazz Pharmaceuticals Trading 3.7% Higher on Heavy Volume; Currently at \$49.77

Financial news for JAZZ dated on 2012-02-06: Jazz Pharmaceuticals Trading 1.8% Higher on Heavy Volume; Currently at \$48.87

Financial news for JAZZ dated on 2012-02-01: Jazz Pharmaceuticals Trading 4.4% Higher on Heavy Volume; Currently at \$48.54

Financial news for JAZZ dated on 2012-02-01: KKR Discloses 24.6% Stake in Jazz Pharma

Financial news for JAZZ dated on 2012-01-30: Jazz Pharmaceuticals Spiking Lower

Financial news for JAZZ dated on 2012-01-27: Jazz Pharmaceuticals Spiking Higher on Heavy Volume

Financial news for JAZZ dated on 2012-01-24: Jazz Pharmaceuticals plc Announces New Executive Appointments

Financial news for JAZZ dated on 2012-01-23: Jazz Pharmaceuticals Spiking Higher on Heavy Volume

Financial news for JAZZ dated on 2012-01-18: Jazz Pharmaceuticals Resumes Trading

Financial news for JAZZ dated on 2012-01-18: PREVIEW: Jazz Pharmaceuticals to Resume Trading at 8:50am

Financial news for JAZZ dated on 2012-01-18: Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals

Financial news for JAZZ dated on 2012-01-18: Hearing Chatter of Pfizer Buyout of Jazz Pharmaceuticals for \$60/Share

Financial news for JAZZ dated on 2012-01-18: Jazz Pharmaceuticals Halted; Pending News

Financial news for JAZZ dated on 2012-01-18: Jazz Pharmaceuticals; Pending News

Financial news for JAZZ dated on 2012-01-11: Jazz Pharma Sees 50% of Revenue to Drop Down to Adj Net

Financial news for JAZZ dated on 2012-01-09: Did John 3:16 Predict These Companies' Successes?

Financial news for JAZZ dated on 2012-01-06: Benzinga's Volume Gainers

Financial news for JAZZ dated on 2012-01-06: Jazz Pharmaceuticals Rallying on Strong Outlook

Financial news for JAZZ dated on 2012-01-06: Jazz Pharmaceuticals Spiking Higher at the Open

Financial news for JAZZ dated on 2012-01-05: Jazz Pharmaceuticals Sees FY 2012 Adjusted EPS of \$4.00 - 4.15 vs \$3.40 Est

Financial news for JAZZ dated on 2012-01-04: Jazz Pharma Says Will Update Azur Acquisition, Xyrem Drug Sales

Financial news for JAZZ dated on 2011-12-30: ETF Showdown: Fun With Pharma

Financial news for JAZZ dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for JAZZ dated on 2011-12-12: Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limited

Financial news for JAZZ dated on 2011-12-08: WBB Securites Downgrades Jazz Pharmaceuticals to Hold

Financial news for JAZZ dated on 2011-11-04: Jazz Pharmaceuticals Spiking Lower on Heavy Volume

Financial news for JAZZ dated on 2011-11-01: End-of-Day Market Summary for November 1, 2011

Financial news for JAZZ dated on 2011-11-01: Jazz Pharmaceuticals Reports Q3 EPS \$0.94 vs \$0.94 Est; Revenues \$73.3M vs \$ 72.03M Est

Financial news for JAZZ dated on 2011-10-18: Jazz Reaffirms Xyrem Sales Forecast of \$215-225M

Financial news for JAZZ dated on 2011-10-18: UPDATE: Piper Jaffray Defends Jazz Pharmaceuticals, Reiterates Overweight and \$51 PT

Financial news for JAZZ dated on 2011-10-18: Piper Jaffray Defends Jazz Pharmaceuticals; Reiterates Overweight and \$51 PT

Financial news for JAZZ dated on 2011-10-18: UPDATE: Jefferies Defending Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-10-18: Jefferies Defending Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-10-18: Jazz Pharmaceuticals Spiking Lower

Financial news for JAZZ dated on 2011-10-17: Piper Jaffray Reiterates Overweight on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-10-13: Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for JAZZ dated on 2011-10-10: Piper Jaffray Overweight on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-09-26: Piper Jaffray Reiterates Overweight on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-09-20: Tuesday Afternoon Movers; Jazz Pharma Up 8%

Financial news for JAZZ dated on 2011-09-20: Benzinga's Volume Movers

Financial news for JAZZ dated on 2011-09-20: UPDATE: Jefferies Raises PT on Jazz Pharma to \$56

Financial news for JAZZ dated on 2011-09-20: Piper Jaffray Overweight on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-09-20: Jefferies Raises PT on Jazz Pharmaceuticals to \$52

Financial news for JAZZ dated on 2011-09-19: Jazz Pharm Resumes Trading

Financial news for JAZZ dated on 2011-09-19: PREVIEW: JAZZ Pharma to Resume Trading at 4:35 p.m.

Financial news for JAZZ dated on 2011-09-19: Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-09-19: Jazz Pharmaceuticals Halted, Pending News

Financial news for JAZZ dated on 2011-09-01: Piper Jaffray: Jazz Pharmaceuticals Not Expecting Payer Pushback In Wake Of Price Hike

Financial news for JAZZ dated on 2011-08-30: Afternoon Movers; Miners Gaining on Higher Gold Price

Financial news for JAZZ dated on 2011-08-22: Hearing Mid-Tier Firm Removed Jazz Pharma from its Buy List

Financial news for JAZZ dated on 2011-08-10: Jazz Pharmaceuticals Positive Mention in Seeking Alpha Blog

Financial news for JAZZ dated on 2011-08-10: Jazz Pharma Spiking Higher on Heavy Volume

Financial news for JAZZ dated on 2011-08-02: Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows

Financial news for JAZZ dated on 2011-08-01: Benzinga's Volume Movers

Financial news for JAZZ dated on 2011-08-01: The Week Ahead, Morning Noteables August 1

Financial news for JAZZ dated on 2011-08-01: UPDATE: Jefferies Upgrades Jazz Pharmaceuticals To Buy, Raises PT To \$52

Financial news for JAZZ dated on 2011-08-01: Jefferies Upgrades Jazz Pharmaceuticals To Buy, Raises PT To \$52

Financial news for JAZZ dated on 2011-07-31: Stocks to Watch for Monday 8/01/2011: Fresh 52 Week Highs and Lows

Financial news for JAZZ dated on 2011-07-29: Jazz Pharmaceuticals Soaring 15%

Financial news for JAZZ dated on 2011-07-29: Jazz Pharmaceuticals up 14% on Upbeat Earnings

Financial news for JAZZ dated on 2011-07-28: Jazz Pharma Reports Q2 EPS \$0.82 vs \$0.77 Est; Revenues \$64.6M vs \$61.86M Est

Financial news for JAZZ dated on 2011-07-20: Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows

Financial news for JAZZ dated on 2011-07-15: July 14th: Top Performing Small Cap Stocks (UFPI, BTH, UTEK, GLUU, JAZZ)

Financial news for JAZZ dated on 2011-07-14: Jazz Pharmaceuticals up Over 5% on Overweight Initiation

Financial news for JAZZ dated on 2011-07-14: Piper Jaffray Initiates Jazz Pharmaceuticals At Overweight, \$51 PT

Financial news for JAZZ dated on 2011-07-07: Hearing Twitter Chatter on Jazz, Previously Locked Up Shares to be Sold Today

Financial news for JAZZ dated on 2011-07-05: Puts Purchased on Jazz Pharmaceuticals

Financial news for JAZZ dated on 2011-06-24: Friday Stock Watchlist: 5 Technical Setups to Watch

Financial news for JAZZ dated on 2011-06-01: Second Wave of Russell ETFs Comes Ashore

Financial news for JAZZ dated on 2011-05-04: Flash Crash Could Still Happen (JAZZ)

Financial news for JAZZ dated on 2011-04-14: Jazz Pharmaceuticals Hits 52-Week High (JAZZ)

Financial news for JAZZ dated on 2011-04-08: Jazz Pharmaceuticals Hits 52-Week High (JAZZ)

Financial news for JAZZ dated on 2011-03-18: Options Brief: Jazz Pharmaceuticals, Inc. (JAZZ)

Financial news for JAZZ dated on 2011-03-17: Buyers Step Back In 03-17-2011

Financial news for JAZZ dated on 2011-03-17: Options Brief: Jazz Pharmaceuticals (JAZZ)

Financial news for JAZZ dated on 2011-03-07: Jazz Pharmaceuticals Reports EPS of \$0.63 vs. \$0.60; Revenues \$53.4M vs. \$51.05M

Financial news for JAZZ dated on 2011-03-02: Five Trade Ideas for Thursday, March 03

Financial news for JAZZ dated on 2011-01-10: Jazz Pharmaceuticals Jumps 8% To New 52-Week High (JAZZ)

Financial news for JAZZ dated on 2011-01-10: Jazz Pharmaceuticals Up 8% After Hitting 52-Week High (JAZZ)

Financial news for JAZZ dated on 2011-01-06: Calls Purchased on Jazz Pharmaceuticals (JAZZ)

Financial news for JAZZ dated on 2010-12-20: Calls Purchased on Jazz Pharmaceuticals (JAZZ)

Financial news for JAZZ dated on 2010-12-13: Puts Purchased on Jazz Pharmaceuticals (JAZZ)

Financial news for JAZZ dated on 2010-12-07: New Analyst Coverage - Screen of the Week

Financial news for JAZZ dated on 2010-12-07: New Analyst Coverage - Screen of the Week

Financial news for JAZZ dated on 2010-11-18: Unconfirmed Rumors continue to swirl that Jazz Pharmaceuticals, Inc. (JAZZ) is a takeover target by (CEPH) at \$22.00 a share

Financial news for JAZZ dated on 2010-11-12: NASDAQ Biotech/Pharma Stock Watch ; (NASDAQ:BPAX), (NASDAQ:MNKD), (NASDAQ:SPPI)

Financial news for JAZZ dated on 2010-11-12: Unconfirmed Rumors that Jazz Pharmaceuticals, Inc. (JAZZ) is a possible takeover target in the mid \$20s possible suitors include Cephalon Inc. (CEPH) and (PFE)

Financial news for JAZZ dated on 2010-11-09: Mad Money Lightning Round: Cramer Likes Honeywell (HON, JAZZ, ICLR, ANDE, DE, TSCO, STD, FCS, BIDU, GOOG, NAT)

Financial news for JAZZ dated on 2010-11-08: NASDAQ Stocks Hitting 52-Week Highs (CCME, JAZZ, RURL, AERL)

Financial news for JAZZ dated on 2010-11-05: Jazz Pharmaceuticals Hits 52-Week High (JAZZ)

Financial news for JAZZ dated on 2010-11-05: Jazz Pharmaceuticals Grooves Higher (JAZZ)

Financial news for JAZZ dated on 2010-11-04: Benzinga's After Hours Gainers (WRLS, JAZZ, IGOI)

Financial news for JAZZ dated on 2010-11-04: Jazz Pharmaceuticals Soars 12% After Hours (JAZZ)

Financial news for JAZZ dated on 2010-11-04: Jazz Pharmaceuticals Announces Q3 EPS of \$.41

Financial news for JAZZ dated on 2010-11-03: Jazz Pharma Downgraded to Buy

Financial news for JAZZ dated on 2010-10-12: Jefferies Downgrades Jazz Pharma to Hold (JAZZ)

Financial news for JAZZ dated on 2010-10-12: Benzinga's Top Downgrades (ALXA, CEO, NBHGY, JAZZ)

Financial news for JAZZ dated on 2010-10-11: Benzinga's Top Pre-Market NASDAQ Losers (JAZZ, ACGY, ARMH, RIMM)

Financial news for JAZZ dated on 2010-10-11: Jazz Pharmaceuticals Receives FDA

Response Regarding its Treatment of Fibromyalgia

Financial news for JAZZ dated on 2010-10-08: Protection Purchased on Jazz Pharmaceuticals (JAZZ)

Financial news for JAZZ dated on 2010-09-03: What's Hot On TheStreet

Financial news for JAZZ dated on 2010-08-23: Tech Stocks Fly, Pharma Stocks Cry! (DELL, HPQ, PAR, CML, CVLT, ISLN, TPL, JAZZ, EPCT, CPIX)

Financial news for JAZZ dated on 2010-08-23: Benzinga's Top Pre-Market NASDAQ Losers (JAZZ, SAFM, PDLI, COCO)

Financial news for JAZZ dated on 2010-08-18: Sector Leaders 08-18-2010

Financial news for JAZZ dated on 2010-08-18: Benzinga's Volume Movers (JAZZ, ENDP, CAGC, STRA)

Financial news for JAZZ dated on 2010-08-18: Jazz Pharmaceuticals Rising After Positive FDA Commentary (JAZZ)

Financial news for JAZZ dated on 2010-08-18: Benzinga's Top Pre-Market NASDAQ Gainers (CRDC, PTEC, JAZZ, JDSU)

Financial news for JAZZ dated on 2010-08-16: Benzinga's Top Pre-Market NASDAQ Gainers (SYUT, EGL, JAZZ, ITMN)

Financial news for JAZZ dated on 2010-08-13: Jefferies Has Some Thoughts On Jazz (JAZZ)

Financial news for JAZZ dated on 2010-08-11: Benzinga's Volume Movers (ASCA, JAZZ, HMIN, MATK)

Financial news for JAZZ dated on 2010-08-10: Jazz Pharmaceuticals Reports Strong Quarter, Ups Guidance (JAZZ)

Financial news for JAZZ dated on 2010-06-15: Benzinga's Top Pre-Market Gainers (FCEL, NLST, JAZZ, HERO)

Financial news for JAZZ dated on 2010-06-15: Benzinga's Top Upgrades (CELG, YSI, JAZZ, TRW)

Financial news for JAZZ dated on 2010-06-15: Barclays Upgrades JAZZ To Overweight

Financial news for JAZZ dated on 2010-05-11: Jazz Pharmaceuticals To Raise \$58.5M In Secondary Offering

Financial news for JAZZ dated on 2010-03-17: Benzinga's Volume Movers (PLCM, ABII, SMTS, JAZZ, RBCN)

Financial news for JAZZ dated on 2010-03-02: Jim Cramer Comments On IVR, CPL, JAZZ

Financial news for JAZZ dated on 2010-01-27: Benzinga's Top Pre-Market Losers (CAT, ZAGG, INSP, JAZZ, FSIN, HERO)

Financial news for JAZZ dated on 2010-01-20: Benzinga's Volume Movers (CREE, RMBS, CETV, JAZZ, ASYS)

Financial news for JAZZ dated on 2009-12-15: NASDAQ's Most Advanced Today (LIMS, ARRY, SGEN, JASO, JAZZ)

Financial news for JAZZ dated on 2009-12-15: Benzinga's Top Pre- Market Gainers (LIMS, SGEN, CLNE, ARRY, JASO, JAZZ, SPWRA)

Financial news for JAZZ dated on 2009-08-17: TheFortuneFinancial.com Free Market Research on CVBF, ESRX, CTAS, FUQI, JAZZ and GILD